Blood and BM Path Chapters 20-21 - MDS and MDS/MPN Flashcards

1
Q

Diagnostic flow diagram in suspected MPN

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

The bone marrow in MDS is usually ____

A

The bone marrow in MDS is usually hypercellular

It is characterized by ineffective hematopoiesis, not asplasia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Defining features of MDS with refractory anemia/thrombocytopenia/neutropenia

A

Dyshematopoiesis in one, two, or all three lineages. (If 2 or more linages, diagnosed as “with multilineage dysplasia”)

<5% bone marrow blasts.

<1% peripheral blasts.

Not meeting criteria for another category.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Defining features of MDS with refractory anemia and ringed sideroblasts

A

Dyshematopoiesis in erythrocytes.

<5% bone marrow blasts.

<1% peripheral blasts.

Ringed sideroblasts comprising >15% of bone marrow erythroblasts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Defining features of MDS with excess blasts

A

Dyshematopoiesis in one, two, or all three lineages.

EB stage I: 5-9% blasts in the bone marrow and <5% circulating blasts

EB stage II: 10-19% blasts in the bone marrow or >5% circulating blasts or Auer rods in a blast

If dysplasia is present, >20% BM blasts automatically puts you in AML with myelodysplastic features

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Defining features of CMML

A

Meeting criteria for any diagnosis of myelodysplastic syndrome

plus

> 1 × 109/L absolute monocytes/promonocytes in peripheral blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

“Minimum” diagnostic criteria for MDS

A

Evidence of dysplasia in >10% of cells of a given lineage in the bone marrow, in the appropriate clinical context

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Translocations and diagnosis of MDS vs AML with myelodysplastic features

A

The holy trinity of hematology, t(15:17), inv(16)/t(16;16), and t(8;21) automatically get a diagnosis of AML irrespective of their blast count.

Any other translocation, including t(9;11), t(6;9), inv(3)/t(3;3), and t(1;22), still need to meet the >20% bone marrow or circulating blasts criterion to qualify as AML. Otherwise, these are diagnosed as MDS with recurrent genetic anomalies. However, they may become a diagnosis of AML on 2 month follow-up biopsies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

MDS with del(5q)

A

Form of MDS with recurrent genetic anomalies

Usually associated with anemia, but normal or even increased platelet count. No or rare blasts in BM.

BM will have normal to increased number of megakaryocytes, but significant megakaryocyte dysplasia with monolobed nuclei is typically present.

This phenotype is due to loss of RPS14, ribosomal protein S14, a component of the 40S ribosome. Selective loss of this gene also produces this phenotype.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Autoimmunity in patients with MDS

A

~10% of patients with MDS have or develop comorbid autoimmune conditions

The TSG interferon regulatory factor-1 (IRF-1) has been linked to this phenomenon. It is frequently overexpressed in MDS, and high expression predisposes to autoimmunity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Elevated serum __ is a poor prognostic factor for MDS

A

Elevated serum LDH is a poor prognostic factor for MDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

DDx for dysgranulopoiesis

A
  • GCSF / GMCSF therapy
  • Viral infections (HIV, EBV)
  • Paraneoplastic condition
  • Immediately post-chemotherapy
  • Drug-induced
    • Bactrim
    • Mofetil
    • Clozapine
    • Methimazole
    • Prophythiouracil
    • Dapsone
    • Beta lactams
    • NSAIDs
    • Anticonvulsants
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

DDx for dysmegakaryocytosis

A

Infections (HIV)

Myelofibrosis (paraneoplastic or autoimmune)

Post-transplant

Post-chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Best staining method to evaluate for MDS

A

Giemsa-Wright

This allows you to see both granulation in neutophils and basophilic stippling in red cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Sideroblastic anemia as a “microcytic anemia”

A

Many textbooks list it this way, but this only applies for hereditary or lead-induced sideroblatic anemia – NOT MDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Acquired Hgb H disease

A

Can rarely occur in the setting of myelodysplasia

This will appear as a perponderance of small, hypochromic red cells in the presence of normal iron studies. These cells will be even more hypochromic than IDA – they will have only a thin lining of red around the periphery, with a ratio of ~1:4 or ~1:5.

Brilliant cresyl blue stain will reveal the characteristic “golf ball” inclusions

17
Q

Associated eosinophilia or basophilia in MDS

A

Portends a poor prognosis

18
Q

MDS with fibrosis

A

Arbitrarily defined as a “moderate to severe” increase in reticulin fiber in the setting of MDS

Diagnosed via reticulin silver stain on trephine biopsy

19
Q

What’s wrong with this picture?

A

This is clearly an erythyroid nest, but none of the cells are immature! What you want to see is nests with cells in various stages of maturation.

This is evidence of dyserythropoiesis.

20
Q

Paratrabecular megakaryocytes

A

Pretty atypical

Suggestive of myelodysplasia

21
Q

Clues to secondary myelodysplasia

A

In secondary cases, stroma is usually affected too:

  • Reticulin deposition
  • Stromal edema
  • Interstitial leakage of red cells
  • In severe cases, gelatinous change (alcian blue positive)

Evidence of prior tissue necrosis also helps:

  • Collagen fibrosis
  • Dead bone trabeculae
  • Dystrophic calcification

A repair-type inflammatory infiltrate is also suggestive:

  • Activated efferocytosing macrophages (gobbling up debris)
  • Perivascular plasma cell infiltrate
  • Reactive lymphoid follicles or granulomas
22
Q

MDS with del(17p)

A

Characterized by myelodysplasia with small, vacuolated neutrophils with monolobed nucleus (Pseudo Pelger-Huet anomaly)

23
Q

MDS with del(20q)

A

Characterized by relatively minimal dysplasia that tends to have more pronounced thrombocytopenia, mimicking ITP

Morphologically, associated with small vacuolated, hypogranular myeloid cells/PMNs that demonstrate erythrophagocytosis

24
Q

MDS with mutated Tet2

A

Positive prognostic factor for MDS

Present in ~20% of cases

25
Q

MDS with mutated nRAS

A

Poor prognosis

10-15% of cases

26
Q

MDS with mutated PIG-A

A

Yes, the same PIG-A as PNH

This group of patients is thought to have an immunologic component to their disease – they have low rates of progression to AML and tend to respond well to immunosuppression.

27
Q

Therapy of choice for MDS with del(5q)

A

These patients respond quite well to lenalidomide, an immunomodulator with pleiotropic effects

It is thought that its efficacy in del5q is explained by its upregulation of SPARC (a tumor suppressor lost with del5q) and its anticytokine signaling activity.

28
Q

Therapy of choice for most MDS

A

5-azacytodine has become accepted as the superior chemotherapeutic for treating MDS, however this only extends the median prognosis from 15 months to 25 months. Decitabine has similar results. They have largely replaced cytarabine for this purpose.

Immunosuppression is effective in young patients with cytogenetically normal MDS without longstanding transfusion requirement.

HSC transplant is the only definitive cure for MDS.

29
Q

Dr. Hasserjian’s “holt trinity” of MDS stains

A

p53, CD34, CD61

30
Q

Dysmyelopoiesis in the setting of marrow lymphoma involvement

A

When lymphomas involve the bone marrow, you can sometimes see morphologic changes associated with dysmyelopoiesis even without cytopenias.

These changes should not necessarily be interpreted as myelodysplastic syndrome, and may simply be reactive changes in the setting of the lymphoma – paricularly a T cell lymphoma.

31
Q

MDS with acquired alpha thalassemia

A

Alpha thalassemia myelodysplastic syndrome (ATMDS)

Associated with mutations in the epigenetic regulator ATRX.

Congenital heterozygous loss is also found and is a rare cause of alpha thalassemia, however is not known to be cancer-associated. Homozygous loss is incompatible with life. As the name suggests, the gene is X-linked.

Loss of ATRX results in activation of alternative telomere lengthening pathways and a variety of other complex epigenetic phenomena.